Back to News
Market Impact: 0.2
MetaVia Inc. to Present Phase 1 Clinical Trial Data for DA-1726 at Precision Liver Symposium 2026
Source: Nasdaq
Healthcare & Biotech
MetaVia said an abstract presenting Phase 1 clinical-trial data for DA-1726, a dual OXM analog targeting GLP-1 and glucagon receptors, was accepted for an oral presentation at the Precision Liver Symposium. The article excerpt provides no trial results, date details, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
MTVA0.40
More News
- Bausch Health raises 2026 outlook as third-quarter adjusted earnings surge 53%
- This hospice services stock is outperforming the S&P 500. Jefferies sees more gains ahead
- Biotechs buck a sluggish IPO market, but investors should tread warily
- Waters’ new AI tool targets one of the pharmaceutical industry’s most tedious tasks
- Dassault Systèmes raises 2026 outlook as revenue growth rebound gathers pace
- Needham initiates Clover Health stock with buy on cohort economics